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Abstract Major histocompatibility complex (MHC) class II
surface levels on thymocytes increase after CD99 ligation.
The functional implication of the up-regulated MHC class II
was assessed by engaging MHC class II on CD99-ligated cells.
MHC class II engagement down-modulated surface levels of T
cell receptor and MHC molecules, and inhibited apoptosis of
CD99-ligated thymocytes and CEM tumor cells, antagonistic
e¡ects on the previously reported CD99 functions. The results
were reproducible regardless of the order of ligation of MHC
class II and CD99. We suggest that signaling via MHC class II
on CD99-engaged cells might be involved in the thymic matu-
ration process by damping CD99 ligation e¡ects.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
During the maturation process, most immature thymocytes
are presumed to die as a result of lack of positive selection
that occurs when T cell receptors (TCRs) recognize peptide/
major histocompatibility complex (MHC) complexes ex-
pressed on selecting cells, such as thymic epithelial cells and
human thymocytes, with appropriate a⁄nity [1^4]. Along the
development process in the thymus, the expression level of
TCR complex on thymocytes is quantitatively regulated with
an increase after positive selection [5].
A 32 kDa surface glycoprotein, CD99, is expressed highly
in immature thymocytes and T cells but moderately in many
other hematopoietic cell types [6,7]. The antigen has been
presumed to be involved in various steps of T cell develop-
ment and di¡erentiation. While CD99 ligation provides pe-
ripheral blood T cells with a co-stimulatory signal in the pres-
ence of suboptimal CD3 stimulation and leads to Th1 cell
di¡erentiation of the engaged T cells [8,9], it stimulates homo-
typic aggregation [10] and apoptosis [11] of thymocytes.
Moreover, CD99 ligation on immature thymocytes induces
up-regulation of MHC molecules and TCR expression on
the cells, suggesting that CD99 is a cell surface protein with
a potential modulatory e¡ect on positive selection by enhanc-
ing the e⁄ciency of TCR^MHC interaction [12].
We previously reported that MHC class II molecules are
expressed in signi¢cant amounts on human fetal and postnatal
thymocytes [13], which is not the case in mice. However, the
biological relevance of MHC class II expression on human
immature and mature T cells is not well understood. MHC
class IIþ double positive (DP) thymocytes are able to posi-
tively select DP thymocytes, leading to di¡erentiation into
CD4þCD83 and CD43CD8þ cells in the in vitro reaggregate
culture system [4]. In this system, di¡erentiation into single
positive (SP) T cells was signi¢cantly blocked by incubation
with anti-MHC class II monoclonal antibodies (mAbs), sug-
gesting a role of MHC II antigens on thymocytes in positive
selection in the human system.
In this paper, to elucidate the functional role of MHC class
II expressed on a human tumor T cell line and thymocytes, we
investigated phenotypic changes related to CD99 function in
immature T cells by incubating cells with anti-HLA-DR
mAbs in addition to anti-CD99 mAb. We show that MHC
class II might play a role in the thymic maturation process,
exerting a negative in£uence on CD99 functioning.
2. Materials and methods
2.1. Cells
CEM T cells were maintained at 37‡C and 5% CO2 in RPMI 1640
(Gibco, Grand Island, NY, USA), supplemented with 10% fetal calf
serum (FCS; Gibco), penicillin at 400 U/ml, and streptomycin at 150
Wg/ml. Human thymuses were obtained from donors undergoing car-
diac surgery at Seoul National University Hospital and were pro-
cessed for single cell suspension of thymocytes as previously described
[12].
2.2. Antibodies
For engagement, cells were incubated with unconjugated forms of
anti-MHC class II (YG18 or 2.06), anti-MHC class I (W6/32), or anti-
CD99 (DN16) mAbs and goat anti-mouse IgG for cross-linking. Anti-
CD1a mAb (OKT6) was used for an isotype-matched control. To
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detect antigens on the cells engaged with unconjugated forms of mAbs
described above, £uorescein isothiocyanate (FITC)-conjugated mAbs
of di¡erent epitopes for MHC class II (L243), MHC class I (YG13),
or CD99 (YG32) were used for staining. The unconjugated forms of
mAbs (YG18, 2.06, W6/32, DN16, and OKT6) and FITC-conjugated
mAbs (YG13, L243, DN16 and YG32) were purchased from DiNonA
(Seoul, Korea). Anti-TCR K-FITC mAb was purchased from Phar-
Mingen (San Diego, CA, USA). Propidium iodide (PI; Becton Dick-
inson, Sunnyvale, CA, USA) and FITC-conjugated annexin V (Phar-
Mingen) were used at 50 Wg/ml and at 1 Wg/ml, respectively.
2.3. Cell engagement with monoclonal antibodies
2U106 cells from CEM T cells and thymocytes were placed into
wells of 24-well tissue culture plates (Corning, Corning, NY, USA)
containing 10% fetal bovine serum^RPMI culture medium and incu-
bated for 30 min at 37‡C in the presence of anti-CD99 (DN16: 1 Wg/
ml) mAb, and then incubated with an isotype-matched control
(OKT6: 10 Wg/ml) or anti-MHC class II (YG18: 10 Wg/ml) mAbs
for an appropriate time (1^30 h). The primary antibodies were
cross-linked by 5^10 Wg/ml of goat anti-mouse IgG.
2.4. Flow cytometric analysis
After engagement with appropriate antibodies, CEM T cells or
thymocytes were washed with phosphate-bu¡ered saline (PBS) twice
and ¢nally with PBS supplemented containing 1% FCS and 0.05%
sodium azide (FACS bu¡er), and were incubated for 30 min on ice
with FITC-conjugated mAbs. After washing twice with the FACS
bu¡er, cells were analyzed on a FACSCalibur (Becton Dickinson).
For apoptosis analysis, engaged cells were washed twice with cold
PBS and resuspended in HEPES bu¡er (10 mM HEPES/NaOH, pH
7.4, 140 mM NaCl, 2.5 mM CaCl2) at a concentration of 1U106 cells/
ml. Cells were incubated with annexin V^FITC and PI for 15 min at
room temperature prior to analysis on FACSCalibur.
3. Results
3.1. MHC class II engagement down-regulates CD99-induced
up-regulation of TCR
To investigate the role of MHC class II antigen expressed
on human T cells, we treated a CEM human T cell line culture
with anti-HLA-DR (YG18) in conjunction with anti-CD99
(DN16) mAb plus secondary Ab and checked whether addi-
tion of anti-MHC class II mAb would have any e¡ect on the
surface level of TCR on CD99-engaged cells. The phenome-
non of up-regulated TCR expression on CD99-engaged cells
[12] was recapitulated in CEM cells, in a dose-dependent man-
ner as well (Fig. 1A). However, co-engagement of MHC class
II and CD99 on CEM cells abolished this phenomenon, with
no e¡ect detected from the cells treated with isotype-matched
control Ab (OKT6) plus anti-CD99 mAb (Fig. 1B). It was
anti-HLA-DR Ab-speci¢c, since treatment of anti-MHC class
I Ab (W6/32) did not show the same phenomenon, while
another clone of anti-MHC class II mAb (2.06) also showed
blocking e¡ect (Fig. 1C). This antagonizing e¡ect of HLA-DR
engagement on CD99-induced TCR up-regulation was ob-
served regardless of the timing of anti-HLA-DR Ab treatment
in relation to CD99 engagement (Fig. 1D) and continued up
until 30 h after initiation of CD99 engagement (Fig. 1E). This
con¢rms that the blocking e¡ect was not because anti-HLA-
DR mAb occupied secondary Ab necessary for CD99 engage-
ment.
Fig. 1. MHC class II engagement inhibits CD99-induced up-regulation of TCR on CEM T cells. A: CEM T cells were engaged with indicated
concentrations of anti-CD99 mAb (DN16) or with medium only for 2 h. Then the cells were stained with FITC-conjugated anti-TCR mAb
and analyzed on a FACSCalibur. B: After engagement with anti-MHC II mAb (YG18) or an isotype-matched control mAb (OKT6) for 30
min, cells were incubated with anti-CD99 mAb (DN16) for 1 h and then analyzed for TCR expression. C: After engagement with anti-CD99
mAb (DN16) for 30 min, cells were engaged for 2 h with indicated clones of anti-MHC II mAb (YG18 or 2.06), anti-MHC I mAb (W6/32),
or a control Ab (OKT6). The cells were analyzed for TCR surface level using £ow cytometry and mean £uorescence intensity (MFI) values are
plotted. D: Engagement with anti-MHC class II mAb (YG18) or a control Ab (OKT6) was followed by (pre-treat), simultaneously done with
(co-treat), or preceded by (post-treat) engagement with anti-CD99 mAb (DN16). After incubation for 24 h, cells were analyzed for TCR surface
level and the MFI values were compared. E: After pre-treatment with anti-MHC II mAb (YG18) or a control Ab (OKT6) for 30 min, cells
were engaged with anti-CD99 mAb (DN16) and then analyzed for TCR levels at indicated time points. The concentrations of Abs used in en-
gagement are 10 Wg/ml for YG18, 2.06, OKT6 and W6/32, and 1 Wg/ml for DN16 all through the experiments, unless otherwise indicated.
A^E: representative data of three independent experiments.
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To see whether the same phenomenon could be observed in
thymocytes, a population of which expresses HLA-DR natu-
rally [13], thymocytes were treated in the same way. As seen in
CEM cells, pre-incubation with anti-HLA-DR Abs (YG18 or
2.06) blocked up-regulation of TCR induced by CD99 engage-
ment (Fig. 2A), more e¡ectively with an increased amount of
the Ab added for pre-incubation (Fig. 2B), whereas treatment
of anti-MHC class I Ab did not show the same phenomenon
(Fig. 2C). This antagonizing e¡ect of HLA-DR engagement
on CD99-induced TCR up-regulation was independent of the
order of engagement of MHC class II and CD99 on thymo-
cytes (Fig. 2D).
3.2. MHC class II ligation inhibits CD99-induced up-regulation
of MHC class II and MHC class I molecules
MHC class I and II molecules are also up-regulated on
thymocytes by CD99 engagement [12]. To examine whether
the blocking e¡ect of anti-HLA-DR mAb would be relevant
to MHC class I and II antigens, surface levels of MHC mol-
ecules were checked on CEM cells treated in the same way. To
detect MHC antigens on the cells engaged with anti-CD99
(DN16) plus anti-HLA-DR (YG18) or anti-MHC class I
(S6/32) mAbs, FITC-conjugated mAbs of di¡erent binding
speci¢city for MHC class I (YG13) and MHC class II
(L243) were used for £ow cytometric analysis. Up-regulation
of MHC class II antigen, which was supposed to occur by
CD99 engagement, was suppressed by pre-treatment with
anti-HLA-DR mAb (YG18: Fig. 3A,B). The inhibitory e¡ect
was HLA-DR-speci¢c and more prominent on MHC class II
antigen level, compared to that on MHC class I antigen (Fig.
3C,D). This antagonizing e¡ect of HLA-DR engagement on
CD99-induced MHC class II up-regulation was reproduced
regardless of the timing of anti-HLA-DR Ab treatment in
relation to CD99 engagement (Fig. 3E) and persisted up to
30 h (Fig. 3G), whereas the inhibitory e¡ect on MHC class I
Fig. 2. MHC class II engagement inhibits CD99-induced up-regulation of TCR on human thymocytes. A: Thymocytes were treated as de-
scribed in Fig. 1B and analyzed for TCR expression using £ow cytometry. B: Thymocytes were engaged with indicated concentrations of anti-
MHC II mAb (YG18) or a control Ab (OKT6) for 30 min and then anti-CD99 mAb (DN16) for 2 h. C,D: Thymocytes were treated and ana-
lyzed for TCR expression as described in Fig. 1C,D. A^D: representative data of three independent experiments.
Fig. 3. MHC class II engagement inhibits CD99-induced up-regula-
tion of MHC class II and MHC class I on CEM T cells. CEM T
cells were engaged in the same way as described in Fig. 1A^E, and
analyzed for MHC class II (A^C,E,G) and for MHC class I
(D,F,H) surface expression.
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expression was not remarkable (Fig. 3F,H). Based on the fact
that CD99-induced up-regulation of surface antigens is medi-
ated via enhanced transport of the antigens present in cyto-
plasm to cell surface [12], we suggest that the insigni¢cant
increase of the surface level of MHC class I after CD99 en-
gagement and unremarkable blocking e¡ect of HLA-DR after
co-engagement with CD99 (Fig. 3D, F, and H) might be due
to the constitutive expression of the antigen on CEM cells at a
high level.
To substantiate the idea, we checked thymocytes, on which
surface levels of MHC class I and II are low to moderate, with
the same method. Up-regulation of both MHC class I and
class II by CD99 engagement was reduced when anti-HLA-
DR mAb YG18 (Fig. 4A,D) or 2.06 (Fig. 4B,E) was treated
before CD99 engagement, which was independent of the tim-
ing of anti-HLA-DR mAb treatment in relation to CD99
engagement (Fig. 4C,F).
This result shows that treatment of thymocytes with anti-
Fig. 4. MHC class II engagement inhibits CD99-induced up-regulation of class II and MHC class I on human thymocytes. Thymocytes were
treated in the same way as described in Fig. 2 and analyzed for MHC class II (A^C) and for MHC class I (D^F).
Fig. 5. MHC class II engagement does not a¡ect CD99 expression. Thymocytes (A) and CEM T cells (B) were engaged with or without indi-
cated clones of anti-MHC II mAbs (YG18 or 2.06), anti-MHC I mAb (W6/32) alone for 30 min. Then, the cells were stained with DN16-
FITC mAb and analyzed on FACSCalibur. The MFI values were plotted. Thymocytes (C) and CEM T cells (D) were co-engaged with DN16
(anti-CD99 mAb) plus YG18 (anti-MHC II mAb) or OTK6 (a control Ab), or treated with goat anti-mouse IgG (GAM) only for 2 h. Then,
the cells were analyzed for CD99 surface level after staining with FITC-conjugated YG32 (anti-CD99) mAb and the MFI values were plotted.
Those are representative data of three independent experiments.
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HLA-DR mAb (YG18 or 2.06) inhibits CD99-induced up-
regulation of all three antigens involved in T^antigen-present-
ing cell (APC) interaction, TCR and MHC class I and II
antigens.
3.3. MHC II ligation does not a¡ect CD99 expression
One possible explanation for the inhibitory e¡ect of anti-
HLA-DR Ab could be that MHC class II engagement in-
duced down-regulation of the surface level of CD99 antigen.
To test this, CEM T cells and human thymocytes incubated
with appropriate mAbs were analyzed for CD99 surface level
by £ow cytometry. Cells engaged with anti-HLA-DR mAb
(YG18 or 2.06) did not show any change in CD99 surface
level as compared to that after engaging cells with control
mAbs (OKT6 and W6/32) (Fig. 5A,B). Co-engagement of
the cells with anti-HLA-DR mAb YG18 and anti-CD99
mAb DN16 did not a¡ect the surface level of CD99 antigen
either (Fig. 5C,D), as detected at a similar level to that after
control co-engagement (YG18 plus control Ab OKT6) by
staining with FITC-conjugated anti-CD99 mAb YG32, of
which the binding speci¢city is di¡erent from that of DN16
[14]. This result shows that the inhibition of CD99-induced
up-regulation of surface antigen by anti-HLA-DR mAb treat-
ment was a direct e¡ect of the binding of the Ab to the MHC
class II antigen, not an indirect one through down-modulation
of CD99 antigen.
3.4. Inhibition of CD99-induced apoptosis by MHC class II
ligation
Engagement of CD99 induces apoptosis of Jurkat T cells
[15], thymocytes [11], and Ewing’s sarcoma cells [16]. To test
whether prior incubation with anti-HLA-DR mAb has an
antagonizing e¡ect against CD99-induced cell apoptosis, thy-
mocytes treated with anti-HLA-DR mAb and anti-CD99
mAb subsequently were checked for apoptosis by £ow cyto-
metric analysis using annexin V^FITC and PI to distinguish
early and intermediate apoptotic cells (annexin Vþ PI3) from
late phase apoptotic cells and dead cells (annexin Vþ PIþ).
The percentage of pro-apoptotic cells (annexin Vþ PI3) was
increased by incubation with anti-CD99 mAb plus control Ab
for 2 h compared to untreated thymocytes. However, the per-
centage was reduced by almost 50% with treatment of anti-
HLA-DR mAb in addition to anti-CD99 mAb, which was
observed from the cells incubated with another type of anti-
HLA-DR mAb (2.06: Fig. 6A). The blocking e¡ect on CD99-
induced apoptosis was more obvious at an early incubation
time in thymocytes than in CEM cells (Fig. 6B,C). The com-
bined results demonstrate that treatment with anti-HLA-DR
mAb plays a signi¢cant role in neutralizing or suppressing
CD99-induced apoptosis of thymocytes.
4. Discussion
In this paper, we focused on the e¡ect of incubation of anti-
HLA-DR mAb on the CD99 ligation-induced phenomenon in
a human T tumor cell line and thymocytes. Anti-CD99 mAb
engagement induced up-regulation of surface expression of
TCR and MHC antigens and apoptosis of thymocytes, how-
ever, pre-, co-, or post-incubation of anti-HLA DR mAb ab-
rogated all these CD99-induced phenotypes. This was not
because the anti-HLA-DR mAb treatment a¡ected surface
expression of CD99, nor did it use up secondary Ab necessary
for CD99 ligation. This is anti-HLA-DR Ab-speci¢c, since
pre-incubation with anti-MHC class I Ab did not show any
signi¢cant di¡erence from CD99 engagement alone.
Enhanced intracellular transport to the cell surface is con-
Fig. 6. Inhibition of CD99-induced apoptosis by MHC class II engagement in human thymocytes and CEM T cells. A: Thymocytes engaged
with anti-MHC II mAb (YG18 or 2.06) or a control Ab (OKT6) for 30 min and then with anti-CD99 mAb (DN16) for 2 h were incubated
for 15 min with annexin V^FITC and PI and analyzed on a FACSCalibur. The numbers at the top of the dot plots indicate the percentage of
cells in the lower right (LR)/upper right (UR) quadrants, respectively. B: Time courses of apoptosis in thymocytes treated as above were plot-
ted. C: The same assay was performed on CEM T cells and then early apoptotic cell populations (annexin Vþ PI3) were compared. The data
are representative of three independent experiments.
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sidered to be a main mechanism for the CD99-induced in-
crease of surface expression of TCR and MHC antigens
[13], as supported by the facts of tight association of the
TCR complex with the cytoplasmic microtubule network
[17] and Rac1 activity-dependent MHC class I and MHC
class II up-regulation after CD99 engagement involving mi-
crotubule assembly [18^20]. These intracellular events might
be associated with signals transduced by CD99 ligation that
elevate intracellular Ca2þ and enhance TCR-dependent cellu-
lar activation [8,9,21]. MHC class II engagement triggers ac-
tivation events including a cascade of protein tyrosine phos-
phorylation, phosphatidylinositol turnover, and an increase in
cytosolic Ca2þ in human B and T cells [22,23]. Surface MHC
class II was co-immunoprecipitated with phospholipase CQ1
on activated human T cells and the Jurkat T cell line,
although the exact mechanism how this complex could be
formed is unclear [24]. The lack of precise information as to
what kinases are physiologically linked to MHC class II for
signal transduction limited our understanding of the linkage
between MHC class II and the CD99-induced signaling path-
ways. Our postulation is that the signals delivered by MHC
class II engagement might converge on the microtubule net-
work with those transduced by CD99 engagement, thereby
blocking the CD99-induced accelerated transport of TCR
and MHC molecules.
A biological role of MHC antigens expressed on APCs is
presenting antigenic peptides to T cells, serving as a ligand for
the TCR from CD4þ T cells [25]. However, the role of the
antigen expressed on T cells during T cell development and
activation is not de¢ned well. The MHC class II molecules
expressed on activated T cells can transduce signals in T cells
to facilitate activation and proliferation in the presence of a
suboptimal range of TCR/CD3 stimulation [26,27]. The only
result, that treatment of anti-HLA-DR mAb in in vitro thy-
mic reaggregate culture delayed the di¡erentiation of imma-
ture thymocytes [4], has suggested the possible importance of
MHC class II engagement during thymocyte development and
di¡erentiation processes in thymus. The result obtained in this
study, inhibition of CD99-induced apoptosis of thymocytes by
incubation with anti-HLA-DR mAb, supports the idea of in-
volvement of MHC class II engagement during thymic devel-
opment. Anti-apoptotic signaling through MHC class II mol-
ecules reported in B cell lines and splenic B cells [28] implies
that MHC class II signaling is related to anti-apoptosis no
matter which cells MHC class II molecules are expressed
on. Based on this, biological relevance of the antagonistic
e¡ect of MHC class II engagement on CD99 ligation-related
phenotypes is proposed that interaction between CD99 and its
ligand initiates the up-regulation of surface molecules, thereby
enhancing positive selection of immature thymocytes, and in-
duces rapid apoptosis of the cells that are still neglected, but
interaction of MHC class II on thymocytes with its ligand,
possibly CD4 (according to epitopes of YG18 and 2.06
mAbs), might antagonize the CD99 e¡ect on surface antigens
and prolong the life span of immature thymocytes, controlling
the overall pace of thymocyte development in thymus. There-
fore, we suggest that the whole process of positive selection
and maturation of immature thymocytes might be a result of
¢ne-tuning between CD99 signaling and counteracting MHC
class II signaling, both of which act to enhance the e⁄ciency
of positive selection all together.
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